[go: up one dir, main page]

AU2001258093A1 - Molecules that modulate ubiquitin-dependent proteolysis and methods for identifying same - Google Patents

Molecules that modulate ubiquitin-dependent proteolysis and methods for identifying same

Info

Publication number
AU2001258093A1
AU2001258093A1 AU2001258093A AU5809301A AU2001258093A1 AU 2001258093 A1 AU2001258093 A1 AU 2001258093A1 AU 2001258093 A AU2001258093 A AU 2001258093A AU 5809301 A AU5809301 A AU 5809301A AU 2001258093 A1 AU2001258093 A1 AU 2001258093A1
Authority
AU
Australia
Prior art keywords
molecules
methods
dependent proteolysis
identifying same
modulate ubiquitin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001258093A
Inventor
Piers Nash
Tony Pawson
Xiaojing Tang
Mike Tyers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mt Sinai Hospital
Original Assignee
Mt Sinai Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mt Sinai Hospital filed Critical Mt Sinai Hospital
Publication of AU2001258093A1 publication Critical patent/AU2001258093A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2001258093A 2000-05-04 2001-05-04 Molecules that modulate ubiquitin-dependent proteolysis and methods for identifying same Abandoned AU2001258093A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20216600P 2000-05-04 2000-05-04
US60/202,166 2000-05-04
US26377401P 2001-01-24 2001-01-24
US60/263,774 2001-01-24
PCT/CA2001/000632 WO2001083518A2 (en) 2000-05-04 2001-05-04 Molecules that modulate ubiquitin-dependent proteolysis and methods for identifying same

Publications (1)

Publication Number Publication Date
AU2001258093A1 true AU2001258093A1 (en) 2001-11-12

Family

ID=26897420

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001258093A Abandoned AU2001258093A1 (en) 2000-05-04 2001-05-04 Molecules that modulate ubiquitin-dependent proteolysis and methods for identifying same

Country Status (5)

Country Link
US (1) US20040072319A1 (en)
EP (1) EP1283879A2 (en)
AU (1) AU2001258093A1 (en)
CA (1) CA2407945A1 (en)
WO (1) WO2001083518A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024999A2 (en) * 2001-09-14 2003-03-27 Novartis Pharma Gmbh THE F-BOX PROTEIN hCdc4 TARGETS CYCLIN E FOR UBIQUITINYLATION AND DEGRADATION
EP1426055A1 (en) * 2002-11-29 2004-06-09 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Targeted protein degradation vehicles (tpdvs), nucleic acid constructs encoding them and their use
EP1469082A1 (en) * 2003-04-16 2004-10-20 Boehringer Ingelheim International GmbH Method of identifying compounds that specifically inhibit the anaphase promoting complex
KR101616603B1 (en) * 2012-10-11 2016-04-28 서울대학교산학협력단 Methyl degron peptide and methods of controlling protein life span
CN104917708B (en) * 2014-03-13 2018-07-06 通用电气公司 Superposed signal sampling apparatus and the method for sampling
CN108350062B (en) 2015-08-06 2022-10-14 达纳-法伯癌症研究所股份有限公司 Targeted protein degradation to attenuate adverse inflammatory responses associated with adoptive T cell therapy
US12023385B2 (en) 2017-02-08 2024-07-02 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation with heterobifunctional compounds
WO2018148440A1 (en) 2017-02-08 2018-08-16 Dana-Farber Cancer Institute, Inc. Regulating chimeric antigen receptors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2179537A1 (en) * 1994-01-04 1995-07-13 Giulio Draetta Ubiquitin conjugating enzymes
US6573094B1 (en) * 1997-10-16 2003-06-03 Baylor College Of Medicine F-box genes and proteins
US6441140B1 (en) * 1998-09-04 2002-08-27 Cell Signaling Technology, Inc. Production of motif-specific and context-independent antibodies using peptide libraries as antigens
US7223556B1 (en) * 1998-10-09 2007-05-29 President And Fellows Of Harvard College Targeted proteolysis by recruitment to ubiquitin protein ligases
WO2003024999A2 (en) * 2001-09-14 2003-03-27 Novartis Pharma Gmbh THE F-BOX PROTEIN hCdc4 TARGETS CYCLIN E FOR UBIQUITINYLATION AND DEGRADATION

Also Published As

Publication number Publication date
EP1283879A2 (en) 2003-02-19
US20040072319A1 (en) 2004-04-15
CA2407945A1 (en) 2001-11-08
WO2001083518A2 (en) 2001-11-08
WO2001083518A3 (en) 2002-07-18
WO2001083518A9 (en) 2002-12-05

Similar Documents

Publication Publication Date Title
AU2002341600A1 (en) Enhanced system, method and medium for certifying and accrediting requirements compliance
WO2003032240A8 (en) Methods and apparatuses for identification
AU2002252550A1 (en) System, method and medium for certifying and accrediting requirements compliance
AU2002227280A1 (en) Protein modification and maintenance molecules
AU2002350109A1 (en) Methods and apparatus for cryo-therapy
AU2002365592A1 (en) Systems and methods for disseminating information
AU2001275112A1 (en) Systems and methods for application service provision
AU3102397A (en) Metalloprotease inhibitors
IL158750A0 (en) Reagents and methods for modulating dkk-mediated interactions
AU2002256990A1 (en) Apoptosis modulator bcl-b and methods for making and using same
AU2002338428A1 (en) Methods and systems for identifying proteins
AU2002318356A1 (en) Protein modification and maintenance molecules
AU2002366242A1 (en) System and method for identifying media
AU2002364610A1 (en) Methods and materials for modulating trpc4
AU2001258093A1 (en) Molecules that modulate ubiquitin-dependent proteolysis and methods for identifying same
AU2001270271A1 (en) Protein modification and maintenance molecules
AU2002364612A1 (en) METHODS AND MATERIALS FOR MODULATING ENaC-BETA
AU2002242763A1 (en) Method and apparatus for identifying sounds
AU2002253883A1 (en) Protein modification and maintenance molecules
AU2002343515A1 (en) Protein modification and maintenance molecules
AU2000268748A1 (en) Method and apparatus for range finding
AU2001286091A1 (en) Methods for identifying modulators of protein interactions
AU2002336529A1 (en) Protein modification and maintenance molecules
AU2001278594A1 (en) Apparatus for and methods of verifying identities
AU2001282772A1 (en) System and method for media audience measurement